StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.41+0.06 (+4.44%)

Close on Nov 17, 2026Market cap $1.43MP/E –Yield –

Transcode Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Transcode Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $17.44M, up 80.7% year over year. For fiscal 2025 it was $13.42M, up 38.3% from the year before. The highest annual figure on record is $13.42M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.42M+38.3%
FY2024Dec 31, 2024$9.71M-20.9%
FY2023Dec 31, 2023$12.26M+19.9%
FY2022Dec 31, 2022$10.23M+271.6%
FY2021Dec 31, 2021$2.75M+868.1%
FY2020Dec 31, 2020$284.46K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.69M+44.0%
Q1 FY2026Mar 31, 2026$5.11M+130.1%
Q4 FY2025Dec 31, 2025$5.48M+50.5%
Q3 FY2025Sep 30, 2025$3.16M+157.5%
Q2 FY2025Jun 30, 2025$2.57M-16.7%
Q1 FY2025Mar 31, 2025$2.22M+26.2%
Q4 FY2024Dec 31, 2024$3.64M+8.2%
Q3 FY2024Sep 30, 2024$1.23M-63.3%
Q2 FY2024Jun 30, 2024$3.08M+3.9%
Q1 FY2024Mar 31, 2024$1.76M-32.1%
Q4 FY2023Dec 31, 2023$3.36M+25.2%
Q3 FY2023Sep 30, 2023$3.34M+9.8%
Q2 FY2023Jun 30, 2023$2.97M+13.2%
Q1 FY2023Mar 31, 2023$2.59M+37.7%
Q4 FY2022Dec 31, 2022$2.69M+109.0%
Q3 FY2022Sep 30, 2022$3.04M+206.6%
Q2 FY2022Jun 30, 2022$2.62M+1137.3%
Q1 FY2022Mar 31, 2022$1.88M+613.4%
Q4 FY2021Dec 31, 2021$1.29M+746.7%
Q3 FY2021Sep 30, 2021$992.95K+1741.0%
Q2 FY2021Jun 30, 2021$211.75K+182.3%
Q1 FY2021Mar 31, 2021$263.76K–
Q4 FY2020Dec 31, 2020$151.82K–
Q3 FY2020Sep 30, 2020$53.94K–
Q2 FY2020Jun 30, 2020$75.00K–

More Transcode Therapeutics figures

See a number that looks wrong?